Emerging Role of Long Non-coding RNAs in Normal and Malignant Hematopoiesis

0
0
0

Emerging Role of Long Non-coding RNAs in Normal and Malignant Hematopoiesis

Introduction

Hematopoiesis is a tightly regulated process involving the differentiation of multipotent hematopoietic stem cells (HSCs) into diverse blood cell lineages. Recent advancements in transcriptome-wide studies have highlighted the critical regulatory roles of non-coding RNAs (ncRNAs), particularly long non-coding RNAs (lncRNAs), in both normal and malignant hematopoiesis. Once dismissed as transcriptional “noise,” lncRNAs are now recognized as vital modulators of gene expression across biological processes, including cell differentiation, pluripotency, and tumorigenesis. This review synthesizes current knowledge on lncRNA characteristics, mechanisms, and their emerging roles in hematopoietic development and hematologic malignancies.

Characteristics and Functions of Long Non-coding RNAs

LncRNAs are defined as RNA transcripts exceeding 200 nucleotides in length, lacking protein-coding potential. Unlike mRNAs, they exhibit distinct features:

  1. Transcriptional Regulation: Most lncRNAs are transcribed by RNA polymerase II (RNAP II), possess 5′ caps and poly-A tails, and undergo splicing. Their expression is highly cell type-specific and dynamically regulated during differentiation.
  2. Evolutionary Conservation: While lncRNA sequences are less conserved than protein-coding genes, their functional roles exhibit higher conservation.
  3. Mechanistic Diversity: LncRNAs regulate gene expression through chromatin remodeling, transcriptional interference, and post-transcriptional modifications. For example:
    • Epigenetic Regulation: LncRNAs recruit chromatin-modifying complexes to specific genomic loci. HOTAIR facilitates Polycomb Repressive Complex 2 (PRC2) binding to the HOXD cluster, promoting H3K27 trimethylation and gene silencing.
    • Transcriptional Control: Some lncRNAs interact with transcription factors or RNA-binding proteins to modulate target gene expression. pncRNA-D binds cyclin D1 and recruits the RNA-binding protein TLS to inhibit histone acetyltransferases CBP/p300, suppressing cyclin D1 transcription.
    • Post-Transcriptional Modulation: LncRNAs influence mRNA stability, splicing, and translation. The lncRNA Rmrp interacts with DEAD-box helicase DDX5 to regulate transcriptional complexes during T helper 17 (Th17) cell differentiation.

The NONCODE database (v5.0) lists 172,216 human lncRNAs, underscoring their vast regulatory potential.

LncRNAs in Normal Hematopoiesis

Erythropoiesis

Erythropoiesis involves the differentiation of erythroid progenitors into enucleated red blood cells. Key lncRNAs include:

  • lincRNA-EPS: Identified in murine models, this erythroid-specific lncRNA represses the pro-apoptotic gene Pycard, enabling erythroblast survival without altering differentiation.
  • alncRNA-EC7: This lncRNA maintains erythrocyte maturation by suppressing BAND3 expression via chromatin interactions. Knockdown of alncRNA-EC7 disrupts erythroid differentiation.
  • Fas-AS1 (Saf): Induced by GATA1 and KLF1 during differentiation, Fas-AS1 downregulates Fas receptor expression, protecting erythroblasts from Fas-mediated apoptosis.

Myeloid Differentiation

Myelopoiesis is governed by transcription factors like PU.1 and C/EBPα, which regulate lncRNAs such as:

  • HOTAIRM1: Located within the HOXA cluster, HOTAIRM1 facilitates all-trans retinoic acid (ATRA)-induced myeloid differentiation by promoting chromatin reorganization. Its knockdown reduces expression of differentiation markers (CD11b, CD18) and HOXA genes.
  • EGO: Expressed during eosinophil development, EGO regulates granule proteins like major basic protein (MBP) and eosinophil-derived neurotoxin (EDN).

Lymphoid Lineage Specification

LncRNAs play pivotal roles in T-cell and B-cell development:

  • NeST (Tmevpg1/IFNG-AS1): In Th1 cells, NeST binds WDR5, a component of histone methyltransferase complexes, to enhance IFNG expression by altering H3K4 methylation at its locus.
  • linc-MAF-4: This Th1-specific lncRNA suppresses the Th2-associated transcription factor MAF by recruiting chromatin modifiers. Its downregulation skews differentiation toward Th2.
  • BALR-2: In B-cell acute lymphoblastic leukemia (B-ALL), elevated BALR-2 correlates with poor prognosis and steroid resistance.

Regulatory T Cells (Tregs) and CD8+ T Cells

  • Flicr: This Foxp3-associated lncRNA destabilizes Foxp3 expression, reducing Treg stability and enhancing antiviral immunity.
  • lncRNA-CD244: In CD8+ T cells, this lncRNA interacts with EZH2 to regulate IFN-γ and TNF-α production, enhancing anti-tuberculosis immunity.

B-Cell Development

  • CRNDE: Highly expressed in pre-B cells and centroblasts, CRNDE regulates metabolic pathways critical for B-cell maturation.

LncRNAs in Malignant Hematopoiesis

Acute Myeloid Leukemia (AML)

  • NEAT1: Repressed by the PML-RARα fusion protein in acute promyelocytic leukemia (APL), NEAT1 is upregulated during ATRA-induced differentiation, suggesting a tumor-suppressive role.
  • RUNXOR: This intragenic lncRNA overlaps with RUNX1, a gene frequently mutated in AML. RUNXOR interacts with RUNX1 enhancers to promote leukemogenesis.
  • IRAIN: Downregulated in high-risk AML, IRAIN binds the IGF1R promoter, implicating it in leukemia stem cell maintenance.

Chronic Myeloid Leukemia (CML)

  • lncRNA-BGL3: Acting as a competitive endogenous RNA (ceRNA), lncRNA-BGL3 sequesters miRNAs that target PTEN, restoring PTEN expression and suppressing Bcr-Abl-mediated transformation.
  • HOTAIR: Overexpression of HOTAIR drives imatinib resistance via PI3K/Akt signaling.

Lymphoid Malignancies

  • FAS-AS1: In non-Hodgkin lymphoma (NHL), FAS-AS1 hypomethylation increases Fas receptor expression, sensitizing cells to apoptosis. EZH2-mediated repression of FAS-AS1 contributes to chemoresistance.
  • MINCR: In MYC-driven Burkitt lymphoma, MINCR facilitates MYC binding to cell cycle gene promoters, sustaining proliferation.

Multiple Myeloma (MM)

  • MEG3: This tumor-suppressive lncRNA promotes osteogenic differentiation of mesenchymal stromal cells (MSCs) by activating BMP4 transcription. Its downregulation in MM disrupts bone homeostasis.
  • MALAT1: Overexpressed in MM, MALAT1 enhances TGF-β signaling by activating Sp1-dependent transcription of LTBP3, a regulator of TGF-β bioavailability.

Myelodysplastic Syndromes (MDS) and Aplastic Anemia (AA)

  • HOXB-AS3: Elevated in MDS, HOXB-AS3 drives myeloid proliferation and is linked to poor prognosis in low-risk patients.
  • TDRG1: In AA, fibroblast growth factor 1 (FGF1) upregulates TDRG1 to enhance MSC proliferation, suggesting a therapeutic target for bone marrow failure.

Conclusion and Future Perspectives

LncRNAs are emerging as master regulators of hematopoietic differentiation and malignancy. Their cell-specific expression and multi-level regulatory mechanisms make them attractive candidates for diagnostic biomarkers and therapeutic targets. For instance, targeting HOTAIRM1 in APL or lncRNA-BGL3 in CML could overcome drug resistance. Future studies should focus on:

  1. Elucidating the structural and functional diversity of lncRNAs in hematopoiesis.
  2. Developing lncRNA-based therapies using CRISPR interference or antisense oligonucleotides.
  3. Validating clinical applications through large-scale cohorts and preclinical models.

As the field advances, lncRNAs may revolutionize the management of hematologic disorders, offering precision medicine approaches tailored to individual molecular profiles.

doi:10.1097/CM9.0000000000000624

Was this helpful?

0 / 0